Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
NNC0471-0119 A · 1 trial · 1 indication
Ratio of the basal-corrected area under the serum NNC0471-0119 concentration time curve from 0 to 30 minutes and 0 to t, where t is the first time the curve is back to basal level after bolus infusion (at most 12 hours). Measured in percentage
| Arm | Type | Description |
|---|---|---|
| Arm 1 | EXPERIMENTAL | A single dose of NNC0471-0119 A, NNC0471-0119 B, NNC0471-0119 D and Faster Aspart at each of 4 visits in random order (four period cross-over) |
| Arm 2 | EXPERIMENTAL | A single dose of NNC0471-0119 A, NNC0471-0119 B, NNC0471-0119 D and Faster Aspart at each of 4 visits in random order (four period cross-over) |
| Arm 3 | EXPERIMENTAL | A single dose of NNC0471-0119 A, NNC0471-0119 B, NNC0471-0119 D and Faster Aspart at each of 4 visits in random order (four period cross-over) |
| Arm 4 | ACTIVE_COMPARATOR | A single dose of NNC0471-0119 A, NNC0471-0119 B, NNC0471-0119 D and Faster Aspart at each of 4 visits in random order (four period cross-over) |
| Name | Type | Description |
|---|---|---|
| NNC0471-0119 A | DRUG | NNC0471-0119 administered once via an insulin pump as one bolus dose on top of a continuous basal rate. The study will last 1-4 months |
| NNC0471-0119 B | DRUG | NNC0471-0119 administered once via an insulin pump as one bolus dose on top of a continuous basal rate. The study will last 1-4 months |
| NNC0471-0119 D | DRUG | NNC0471-0119 administered once via an insulin pump as one bolus dose on top of a continuous basal rate. The study will last 1-4 months |
| Faster aspart | DRUG | Faster aspart administered once via an insulin pump as one bolus dose on top of a continuous basal rate. The study will last 1-4 months |
Inclusion Criteria: * Male participant or female participant of non-childbearing potential. Non-childbearing potential being defined as surgically sterilised (i.e. documented hysterectomy, bilateral salpingectomy or bilateral oophorectomy) or being postmenopausal (defined as no menses for 12 months...
NNC0471-0119 A is an investigational small molecule being developed for the treatment of Type 1 Diabetes Mellitus. It is designed to be administered via an insulin pump. The drug is currently in Phase 1 clinical development and is not yet approved by regulatory authorities.
The specific molecular target of NNC0471-0119 A has not been disclosed. It is a small molecule being studied for its effects on glucose metabolism in people with Type 1 Diabetes Mellitus. The drug is administered via an insulin pump to evaluate how it works in the body.
NNC0471-0119 A is being developed by Novo Nordisk A/S, a pharmaceutical company listed on the stock exchange under the ticker symbol NVO. The company is conducting clinical research to evaluate the drug's safety and efficacy in patients with Type 1 Diabetes Mellitus.
NNC0471-0119 A is in Phase 1 clinical development. A Phase 1 study has been completed, which involved 19 participants with Type 1 Diabetes Mellitus. The drug is still investigational and has not received approval from the FDA or other regulatory agencies.
NNC0471-0119 A has one completed clinical trial registered under the identifier NCT05262595. This Phase 1 study examined how the drug works in the body when injected by an insulin pump in people with Type 1 Diabetes. The trial was conducted in Austria and enrolled 19 adult participants.
NNC0471-0119 A is an investigational small molecule, not a conventional insulin product. It is being studied for use in Type 1 Diabetes Mellitus, where it is administered via an insulin pump. The drug's mechanism of action is not disclosed, and it is not known to be identical to any approved insulin.